Beraprost sodium for pulmonary hypertension with congenital heart disease

Pediatrics International

Volumn 44, Issue 5, 2002, Pages 528-529

  Suzuki, Hiroshi ^a   Sato, Shi ^a   Tanabe, Saori ^a   Hayasaka, Kiyoshi ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Braprost sodium; Congenital heart disease; Pulmonary hypertension

Indexed keywords

BERAPROST; DIGOXIN; DIURETIC AGENT; OXYGEN;

AGE; AORTOGRAPHY; ARTICLE; BREATHING; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOWN SYNDROME; ECHOCARDIOGRAPHY; FEEDING BEHAVIOR; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HUMAN; INFANT; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG BLOOD VESSEL; MALE; OXYGEN SATURATION; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SHUNTING; SURGICAL TECHNIQUE; TACHYPNEA; TIME;

DOWN SYNDROME; EPOPROSTENOL; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; VASODILATOR AGENTS;

EID: 0036378249     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200X.2002.01597.x     Document Type: Article

References (10)

1. Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997; 349: 1365.
2. Saji T, Ozawa Y, Ishikita T, Matsuura H, Matsuo N. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am. J. Cardiol. 1996; 78: 244-7.
3. Ichida F, Uese K, Hamamichi Y et al. Chronic effects of oral prostacyclin analogue on thromboxane A2 and prostacyclin metabolites in pulmonary hypertension. Acta Pediatr. Jpn. 1998; 40: 14-19.
4. Yoshitomi Y, Kojima S, Kuramochi M. Long-term effect of a new oral prostacyclin analogue, beraprost sodium, in isolated peripheral pulmonary artery stenosis in the adult. J. Intern. Med. 1999; 246: 227-30.
5. Besterman E. Atrial septal defect with pulmonary hypertension. Br. Heart J. 1961; 23: 587-98.
6. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N. Engl. J. Med. 1998; 338: 273-7.
7. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858-65.
8. Nagaya N, Uematsu M, Okano Y et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. Am. J. Coll. Cardiol. 1999; 34: 1188-92.
9. Yuki H, Sato S, Arisaka Y, Kato S, Tomoike H. Orally administered beraprost sodium inhibits pulmonary hypertension induced by monocrotaline in rats. Tohoku J. Exp. Med. 1994; 173: 371-5.
10. Yamaki S, Horiuchi T, Sekino Y. Quantitative analysis of pulmonary vascular disease in simple cardiac anomalies with Down syndrome. Am. J. Cardiol. 1983; 51: 1502-6.